Targeting the Hippo Pathway for Breast Cancer Therapy
暂无分享,去创建一个
[1] K. Guan,et al. Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction. , 2018, Molecular cell.
[2] S. Bicciato,et al. Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4 , 2018, Nature Medicine.
[3] A. Rosenwald,et al. TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells , 2018, Nature Communications.
[4] T. Ahern,et al. Statins: a role in breast cancer therapy? , 2018, Journal of internal medicine.
[5] Xiaolong Yang,et al. The Hippo Pathway: Immunity and Cancer , 2018, Cancers.
[6] H. Shen,et al. A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis , 2018, Nature Communications.
[7] Christian N. Cunningham,et al. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors , 2018, Cancers.
[8] Dana M. Brantley-Sieders,et al. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ , 2017, Science Signaling.
[9] T. Borin,et al. Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines. , 2017, Anti-cancer agents in medicinal chemistry.
[10] W. Barry,et al. An open label, phase II trial of continuous low-irradiance photodynamic therapy (CLIPT) using verteporfin for the treatment of cutaneous breast cancer metastases. , 2017 .
[11] M. Duffy,et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). , 2017, European journal of cancer.
[12] Min Hwan Kim,et al. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies , 2016, Cellular and Molecular Life Sciences.
[13] D. Berry,et al. Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial , 2017 .
[14] Michael B. Stadler,et al. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα , 2017, Nature.
[15] Matthew V. Holt,et al. The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity , 2016, Cell.
[16] Lisheng Wang,et al. Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression , 2016, Journal of biomedical research.
[17] E. Winer,et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.
[18] K. Irvine,et al. Cellular Organization and Cytoskeletal Regulation of the Hippo Signaling Network. , 2016, Trends in cell biology.
[19] Tuan S. Nguyen,et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. , 2016, Cancer discovery.
[20] A. Fields,et al. PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis , 2016, Oncogene.
[21] Davide Esposito,et al. Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations , 2016, Oncotarget.
[22] B. N. Devaiah,et al. BRD4 is a Histone Acetyltransferase that Evicts Nucleosomes from Chromatin , 2016, Nature Structural &Molecular Biology.
[23] Valerie M. Weaver,et al. Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors , 2015, Molecular biology of the cell.
[24] Junjie Chen,et al. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins. , 2015, Cell reports.
[25] B. Győrffy,et al. Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1 , 2015, Science Signaling.
[26] R. Pazdur,et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer , 2015, Clinical Cancer Research.
[27] M. Ying,et al. Abstract 4444: Small molecule drug Verteporfin inhibits TAZ/YAP-driven signaling and tumorigenicity of breast cancer cells , 2015 .
[28] K. Guan,et al. Opposing roles of conventional and novel PKC isoforms in Hippo-YAP pathway regulation , 2015, Cell Research.
[29] I. Vitale,et al. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications , 2015, Expert Reviews in Molecular Medicine.
[30] Yasufumi Yamamoto,et al. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers , 2015, FEBS open bio.
[31] Xiaolong Yang,et al. Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling , 2015, Oncotarget.
[32] J. Palacios,et al. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. , 2015, Endocrine-related cancer.
[33] R. Gelber,et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] Bonnie L Boster,et al. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[35] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[36] J. Luk,et al. Targeting Hippo pathway by specific interruption of YAP‐TEAD interaction using cyclic YAP‐like peptides , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[37] A. Mercurio,et al. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells , 2015, Genes & development.
[38] G. Semenza,et al. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype , 2014, Oncotarget.
[39] Dietrich Büsselberg,et al. Auranofin, an Anti-Rheumatic Gold Compound, Modulates Apoptosis by Elevating the Intracellular Calcium Concentration ([Ca2+]i) in MCF-7 Breast Cancer Cells , 2014, Cancers.
[40] J. Asara,et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. , 2014, Cell reports.
[41] Maxime Blijlevens,et al. Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets , 2014, Oncotarget.
[42] S. Dupont,et al. The biology of YAP/TAZ: hippo signaling and beyond. , 2014, Physiological reviews.
[43] R. Maria,et al. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy , 2014, Oncotarget.
[44] S. Cohen,et al. Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover , 2014, The EMBO journal.
[45] W. Jung,et al. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. , 2014, International journal of clinical and experimental pathology.
[46] D. Kalderon,et al. Coupling of Hedgehog and Hippo pathways promotes stem cell maintenance by stimulating proliferation , 2014, The Journal of cell biology.
[47] P. Khanal,et al. YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway. , 2014, Cancer research.
[48] Prashant Kumar,et al. Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer. , 2014, Cancer genomics & proteomics.
[49] Xaralabos Varelas,et al. The Transcriptional Regulators TAZ and YAP Direct Transforming Growth Factor β-induced Tumorigenic Phenotypes in Breast Cancer Cells*♦ , 2014, The Journal of Biological Chemistry.
[50] M. Biffoni,et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells , 2014, Oncogene.
[51] Lin Mei,et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility , 2013, Proceedings of the National Academy of Sciences.
[52] S. Dedhar,et al. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase , 2013, Nature Communications.
[53] G. Halder,et al. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment , 2013, Nature Reviews Drug Discovery.
[54] W. Hong,et al. Actin-binding and Cell Proliferation Activities of Angiomotin Family Members Are Regulated by Hippo Pathway-mediated Phosphorylation* , 2013, The Journal of Biological Chemistry.
[55] P. Bult,et al. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer , 2013, Cellular Oncology.
[56] Xiaolong Yang,et al. BMP4 is a novel transcriptional target and mediator of mammary cell migration downstream of the Hippo pathway component TAZ. , 2013, Cellular signalling.
[57] P. Maroni,et al. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. , 2013, European journal of cancer.
[58] Qifeng Yang,et al. Prognostic significance of mammalian sterile 20-like kinase 1 in breast cancer , 2013, Tumor Biology.
[59] F. Camargo,et al. The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense. , 2013, Cell reports.
[60] Robert P. Jenkins,et al. Mechano-transduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer associated fibroblasts , 2013, Nature Cell Biology.
[61] K. Guan,et al. The Hippo pathway: regulators and regulations. , 2013, Genes & development.
[62] R. Hynes,et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain , 2012, Proceedings of the National Academy of Sciences.
[63] F. Camargo,et al. The Hippo signaling pathway and stem cell biology. , 2012, Trends in cell biology.
[64] Jun O. Liu,et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.
[65] Zhongmei Zhou,et al. Tumorigenesis and Neoplastic Progression YAP Promotes Breast Cell Proliferation and Survival Partially through Stabilizing the KLF 5 Transcription Factor , 2012 .
[66] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[67] Diego Miranda-Saavedra,et al. TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer , 2012, Nature Communications.
[68] S. Bicciato,et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.
[69] N. Ibrahim,et al. Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study , 2011, Clinical Cancer Research.
[70] Y. She,et al. LATS1 tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization , 2011, Cell Research.
[71] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[72] Karen A Gelmon,et al. Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.
[73] Xiaolong Yang,et al. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. , 2011, Cancer research.
[74] S. Lowe,et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma , 2011, Oncogene.
[75] G. Halder,et al. Hippo signaling: growth control and beyond , 2011, Development.
[76] Y. Xiong,et al. PP1 Cooperates with ASPP2 to Dephosphorylate and Activate TAZ* , 2010, The Journal of Biological Chemistry.
[77] Ricardo H Álvarez,et al. Present and future evolution of advanced breast cancer therapy , 2010, Breast Cancer Research.
[78] Xiaolong Yang,et al. LATS tumor suppressor: A new governor of cellular homeostasis , 2010, Cell cycle.
[79] Zhengyu Zha,et al. The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase* , 2010, The Journal of Biological Chemistry.
[80] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[81] K. McMasters,et al. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer , 2010, Cancer.
[82] Frederic A. Fellouse,et al. The Hippo pathway regulates Wnt/beta-catenin signaling. , 2010, Developmental cell.
[83] Yan Sun,et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] A. Knebel,et al. JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis , 2010, Cell Death and Disease.
[85] M. Khanfar,et al. Semisynthetic Latrunculin Derivatives as Inhibitors of Metastatic Breast Cancer: Biological Evaluations, Preliminary Structure–Activity Relationship and Molecular Modeling Studies , 2010, ChemMedChem.
[86] C. Hudson,et al. c-Abl phosphorylation of ΔNp63α is critical for cell viability , 2010, Cell Death and Disease.
[87] Zhengyu Zha,et al. TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition* , 2009, Journal of Biological Chemistry.
[88] K. Gelmon,et al. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model , 2009, Breast Cancer Research.
[89] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] Brian A. Hemmings,et al. NDR Kinase Is Activated by RASSF1A/MST1 in Response to Fas Receptor Stimulation and Promotes Apoptosis , 2008, Current Biology.
[91] Jiandie D. Lin,et al. TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.
[92] C. Mein,et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast , 2008, Cell Death and Differentiation.
[93] Q. Zeng,et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. , 2008, Cancer research.
[94] W. Deng,et al. The Hippo Pathway Promotes Notch Signaling in Regulation of Cell Differentiation, Proliferation, and Oocyte Polarity , 2008, PloS one.
[95] Q. Zeng,et al. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. , 2008, Cancer cell.
[96] M. Khanfar,et al. Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. , 2008, Journal of natural products.
[97] R. Jaenisch,et al. YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells , 2007, Current Biology.
[98] Erica A Golemis,et al. Selective Raf inhibition in cancer therapy , 2007, Expert opinion on therapeutic targets.
[99] Walter Kolch,et al. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. , 2007, Molecular cell.
[100] Y. Shaul,et al. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73 , 2007, Cell Death and Differentiation.
[101] V. Gandin,et al. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. , 2007, Free radical biology & medicine.
[102] Y. Miyoshi,et al. Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers , 2007, Journal of Cancer Research and Clinical Oncology.
[103] Nahum Sonenberg,et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.
[104] Jianmin Zhang,et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon , 2006, Proceedings of the National Academy of Sciences.
[105] Judit Villén,et al. A Conserved MST-FOXO Signaling Pathway Mediates Oxidative-Stress Responses and Extends Life Span , 2006, Cell.
[106] M. Berger,et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.
[107] J. Forbes,et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.
[108] L. Ford,et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.
[109] C. Caldas,et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[111] Vikas Khurana,et al. Statins to reduce breast cancer risk: A case control study in U.S. female veterans , 2005 .
[112] G. Blandino,et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. , 2005, Molecular cell.
[113] P. Opolon,et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[114] Walter Kolch,et al. Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1 , 2004, Science.
[115] Xiaolong Yang,et al. LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1 , 2004, Nature Cell Biology.
[116] R. Schiff,et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.
[117] N. Navin,et al. WW Domain-containing Protein YAP Associates with ErbB-4 and Acts as a Co-transcriptional Activator for the Carboxyl-terminal Fragment of ErbB-4 That Translocates to the Nucleus* , 2003, Journal of Biological Chemistry.
[118] Jonathan Chernoff,et al. Apoptotic Phosphorylation of Histone H2B Is Mediated by Mammalian Sterile Twenty Kinase , 2003, Cell.
[119] R. Sékaly,et al. HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation , 2002, Cell Death and Differentiation.
[120] A. Howell,et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] T. Xu,et al. Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G2/M arrest or apoptosis , 2001, Oncogene.
[123] L. Castagnoli,et al. Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity* , 2001, The Journal of Biological Chemistry.
[124] C. Haipek,et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. , 2001, Genes & development.
[125] Katsuyoshi Hatakeyama,et al. Zyxin, a Regulator of Actin Filament Assembly, Targets the Mitotic Apparatus by Interacting with H-Warts/Lats1 Tumor Suppressor , 2000, The Journal of cell biology.
[126] W. Tao,et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction , 1999, Nature Genetics.
[127] M. Dukes,et al. The preclinical pharmacology of “Arimidex” (Anastrozole; ZD1033) — a potent, selective aromatase inhibitor , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[128] Doriano Fabbro,et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase , 1996, Nature Medicine.
[129] Xiaolong Yang,et al. Targeting the Hippo Pathway to Improve Response to Chemotherapy , 2019, Targeting Cell Survival Pathways to Enhance Response to Chemotherapy.
[130] T. K. Eisinger-Mathason,et al. Targeting the Hippo pathway: Clinical implications and therapeutics. , 2016, Pharmacological research.
[131] Ceshi Chen,et al. Hippo pathway in mammary gland development and breast cancer. , 2015, Acta biochimica et biophysica Sinica.
[132] G. Giamas,et al. LATS2 is a modulator of estrogen receptor alpha. , 2013, Anticancer research.
[133] Zhongmei Zhou,et al. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. , 2012, Carcinogenesis.
[134] K. Gelmon,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[135] F. Cardoso,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[136] K. Guan,et al. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). , 2010, Genes & development.
[137] G. Melino,et al. Yes-Associated Protein (YAP) is a critical mediator of c-Jun-dependent apoptosis , 2008, Cell Death and Differentiation.
[138] J. Downward,et al. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. , 2003, Molecular cell.
[139] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.